Back

At-home screening for Chlamydia trachomatisbased on a self-collected vaginal swab specimen.
Samples are analysed by a certified laboratory.

Chlamydia trachomatis infection is frequently asymptomatic, particularly in women, and may remain undetected in the absence of routine screening. Persistent untreated infection is associated with adverse reproductive health outcomes. Molecular testing constitutes an established component of evidence based screening strategies for the early identification of infection and appropriate clinical follow up.

This product is intended for screening and risk assessment purposes only and is not designed to diagnose disease or replace clinician directed care pathways.

Available soon — Greece only (Phase 1).
Detailed information regarding analytical performance characteristics, intended use, limitations, and procedural requirements will be provided upon official product launch.